AU Patent

AU2017205268A1 — CNP prodrugs with large carrier moieties

Assigned to Ascendis Pharma Endocrinology Division AS · Expires 2018-06-07 · 8y expired

What this patent protects

The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety -Z that is conjugated through a moiety -L

USPTO Abstract

The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety -Z that is conjugated through a moiety -L

Drugs covered by this patent

Patent Metadata

Patent number: AU2017205268A1
Jurisdiction: AU
Classification: —
Expires: 2018-06-07
Drug substance claim: No
Drug product claim: No
Assignee: Ascendis Pharma Endocrinology Division AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.